Production (Stage)
Autolus Therapeutics plc
AUTL
$1.54
$0.010.65%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -14.16% | 496.00% | 82.71% | 40.22% | 40.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -14.16% | 496.00% | 82.71% | 40.22% | 40.22% |
| Cost of Revenue | 20.82% | 15.23% | 166.65% | 75.94% | 64.98% |
| Gross Profit | -22.96% | -10.63% | -173.87% | -78.66% | -66.77% |
| SG&A Expenses | 90.03% | 100.12% | 137.59% | 106.90% | 92.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.87% | 41.58% | 64.34% | 43.51% | 31.55% |
| Operating Income | -49.39% | -37.18% | -63.58% | -43.69% | -31.08% |
| Income Before Tax | -5.92% | -5.15% | -94.89% | -65.14% | -51.86% |
| Income Tax Expenses | 29,023.08% | 8,136.84% | -99.79% | -100.01% | -100.22% |
| Earnings from Continuing Operations | -7.62% | -5.89% | -70.85% | -50.88% | -45.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.62% | -5.89% | -70.85% | -50.88% | -45.96% |
| EBIT | -49.39% | -37.18% | -63.58% | -43.69% | -31.08% |
| EBITDA | -50.25% | -37.94% | -65.95% | -45.96% | -33.36% |
| EPS Basic | 25.80% | 27.50% | -20.01% | 4.03% | 14.61% |
| Normalized Basic EPS | 27.05% | 26.74% | -51.80% | -8.46% | 10.98% |
| EPS Diluted | 25.80% | 27.50% | -20.01% | 4.03% | 14.61% |
| Normalized Diluted EPS | 27.05% | 26.74% | -51.80% | -8.46% | 10.98% |
| Average Basic Shares Outstanding | 43.05% | 46.67% | 47.70% | 53.22% | 60.75% |
| Average Diluted Shares Outstanding | 43.05% | 46.67% | 47.70% | 53.22% | 60.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |